Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target Activated CIK for Advanced Breast Cancer
NCT03524261Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- May 2019
- Primary completion
- Apr 2020
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of activated CIK cells + anti-CD3-MUC1 bispecific antibody in breast cancer, sponsored by Fuda Cancer Hospital. Planned start May 2019; status: withdrawn.
02
Drugs
activated CIK cells + anti-CD3-MUC1 bispecific antibody
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03524261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524261.